NFKB1 and metabolic dysfunction-associated steatotic liver disease: The TNFα-[NF-κB] axis directly induces the expression of the FXR repressor YY1, another unique target for NAFLD/NASH drug discovery.669 If one wishes to enhance the expression and activity of FXR in NAFLD or NASH, it is then natural to wish to inhibit the activity of or repress the expression of YY1.